Zogenix offers Data for Fintepla, Markets React Negatively
Zogenix (ZGNX) stock tumbled as the company reported mixed data from its Phase 3 clinical trial of Fintepla. The trial involved evaluating two doses of the lead drug candidate in patients suffering from a severe form of childhood onset epilepsy called Lennox-Gastaut syndrome. While the drug met the primary endpoint of change in seizure frequency at the higher dose, its lower dose failed to demonstrate statistically significant results.
The trial showed that Fintepla reduced the median frequency of monthly drop seizures by 26.5 percent in comparison to